ARMATA PHARMACEUTICALS, INC. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
ARMATA PHARMACEUTICALS, INC. (ARMP) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $35.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-08-12
- ARMATA PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2026-06-30 was $24.00K.
- ARMATA PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2026-03-31 was $11.00K, a 22.22% increase year-over-year.
- ARMATA PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-03-31 was $9.00K.
- ARMATA PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- ARMATA PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $977.00K, a 63.81% decline from fiscal 2023.
- ARMATA PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $2.70M, a 68.85% decline from fiscal 2022.
- ARMATA PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $8.67M, a 66.73% decline from fiscal 2021.
- ARMATA PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2021 was $26.06M.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | $24.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $35.00K 10-Q · filed 2026-08-12 | ||
| 2026-03-31 | $11.00K 10-Q · filed 2026-05-13 | |||
| 2025-03-31 | $9.00K 10-Q · filed 2026-05-13 | $9.00K derived: sum of 2 quarters · filed 2026-05-13 | ||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $977.00K 10-K · filed 2026-03-25 | ||
| 2024-09-30 | $977.00K 10-Q · filed 2025-11-12 | |||
| 2023-12-31 | $187.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-21 | $2.70M 10-K · filed 2025-03-21 | ||
| 2023-09-30 | $2.51M 10-Q · filed 2024-11-13 | |||
| 2022-12-31 | $8.67M 10-K · filed 2024-03-21 | |||
| 2021-12-31 | $26.06M 10-K · filed 2023-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |